Integrated BioPharma, Inc. (INBP)

Integrated BioPharma Financials Overview

Financials in millions USD. Fiscal year is July - June.

Revenue & Profits

Chart

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Jun 30, 2025	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022	Jun 30, 2021
Revenue Revenue Growth	48.25	54.35	50.32	50.67	56.25	63.56
Revenue Growth	-8.83%	8.02%	-0.70%	-9.91%	-11.51%	20.45%
Gross Profit Gross Profit Growth	2.24	5.56	3.88	4.06	6.55	9.48
Operating Income Operating Income Growth	-1.25	2.02	0.25	0.12	2.75	5.78
Net Income Net Income Growth	-1.65	0.81	0.11	-0.03	3.84	8.01
Earnings Per Share EPS Growth	-0.05	0.03	0.00	-0.00	0.12	0.25
EPS Growth	-	635.32%	-	-	-52.00%	92.31%

Revenue by Segment

Chart

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Jun 30, 2025	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022	Jun 30, 2021
Contract Manufacturing Contract Manufacturing Growth	46.49	51.68	48.57	48.28	54.09	61.84
Other Nutraceutical Businesses Other Nutraceutical Businesses Growth	1.76	2.67	1.75	2.4	2.16	1.72
Total Total Growth	48.25	54.35	50.32	50.67	56.25	63.56

Cash & Debt

Chart

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Jun 30, 2025	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022	Jun 30, 2021
Cash & Investments Cash & Investments Growth	5.83	3.62	1.68	1.32	0.34	0.28
Total Debt Total Debt Growth	3.35	1.02	1.8	2.67	2.06	6
Net Cash (Debt) Net Cash Growth	2.48	2.6	-0.12	-1.36	-1.71	-5.72
Net Cash Growth	35.89%	-	-	-	-	-
Net Cash Per Share Net Cash Per Share Growth	0.08	0.08	-0.00	-0.05	-0.05	-0.18

Cash Flow & CapEx

Chart

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Jun 30, 2025	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022	Jun 30, 2021
Operating Cash Flow Operating Cash Flow Growth	3.03	2.07	0.94	1.23	4.09	3.05
Capital Expenditures CapEx Growth	-0.19	-0.19	-0.55	-0.12	-0.49	-0.3
Free Cash Flow Free Cash Flow Growth	2.84	1.87	0.39	1.12	3.61	2.76
Free Cash Flow Growth	201.70%	380.51%	-65.05%	-69.04%	30.85%	144.89%

Margins

Chart

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Jun 30, 2025	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022	Jun 30, 2021
Gross Margin	4.64%	10.23%	7.72%	8.01%	11.65%	14.92%
Operating Margin	-2.58%	3.72%	0.50%	0.24%	4.88%	9.10%
Pretax Margin	-2.32%	3.79%	0.53%	0.20%	4.62%	11.40%
Profit Margin	-3.43%	1.49%	0.22%	-0.07%	6.82%	12.61%
FCF Margin	5.88%	3.45%	0.78%	2.20%	6.41%	4.33%

Valuation

Chart

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Aug 31, 2026	Jun 30, 2025	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022	Jun 30, 2021
PE Ratio	-	13.72	56.44	-	3.90	4.09
P/FCF Ratio	1.97	5.92	16.21	8.89	4.15	11.90
PS Ratio	0.12	0.20	0.13	0.20	0.27	0.52

Data Source: S&P Global Market Intelligence Last updated: Mar 31, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Aug 26, 2026

Data Sources Report a data error